Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended December 31, 2024, and provided recent corporate updates.
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy of Dermatology (AAD) Meeting in Orlando, FL. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling t
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) will be presented in a late-breaking oral session at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place March 7-11 in Orlando, FL. Bempikibart is a fully human anti-IL-7Rα antibody that
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in two upcoming investor conferences in March:
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to focus on the advancement of its bempikibart clinical development program for the treatment of patients with alopecia areata (AA). As part of the restructuring, the Company is discontinuing the Phase 2 renal basket clinical trial of ADX-097 and is evaluating strategic options for its tissue-targeted
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a virtual company presentation at 4:00 p.m. E.T. on Tuesday, February 11, 2025 at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CLRB | 51.71% | $15.43M | -91.59% | 0.00% |
PLAY | 29.88% | $726.55M | -69.86% | 0.00% |
VRA | 26.89% | $64.05M | -66.03% | 0.00% |
ANAB | 26.34% | $581.14M | -15.85% | 0.00% |
CARM | 26.17% | $13.78M | -85.46% | 0.00% |
ARVN | 24.54% | $521.98M | -81.61% | 0.00% |
AGIO | 23.36% | $1.73B | +3.56% | 0.00% |
RGNX | 21.93% | $392.17M | -62.84% | 0.00% |
GYRE | 21.53% | $786.49M | -47.88% | 0.00% |
VSTM | 21.49% | $318.70M | -47.54% | 0.00% |
ADPT | 20.91% | $1.14B | +138.94% | 0.00% |
CACI | 20.08% | $8.37B | -1.44% | 0.00% |
GTN | 19.93% | $437.65M | -31.80% | 7.58% |
VIRC | 19.72% | $155.24M | -12.81% | 1.00% |
ALEC | 19.63% | $127.82M | -78.57% | 0.00% |
NTRS | 19.52% | $18.94B | +9.26% | 3.12% |
KROS | 19.48% | $437.66M | -83.70% | 0.00% |
CATX | 19.23% | $162.91M | -81.51% | 0.00% |
WBX | 19.07% | $83.14M | -76.94% | 0.00% |
IMNM | 18.99% | $607.78M | -71.68% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
EWW | -0.01% | $1.50B | 0.5% |
SGOL | 0.03% | $4.72B | 0.17% |
HEWJ | 0.03% | $374.18M | 0.5% |
IGRO | -0.05% | $1.02B | 0.15% |
PWZ | -0.06% | $694.97M | 0.28% |
GLDM | -0.08% | $12.98B | 0.1% |
AAAU | -0.09% | $1.27B | 0.18% |
BSCQ | -0.10% | $4.27B | 0.1% |
IQLT | 0.15% | $8.97B | 0.3% |
IEZ | 0.15% | $156.28M | 0.4% |
TAXF | 0.20% | $513.85M | 0.29% |
EWZS | 0.21% | $129.97M | 0.6% |
AGZ | -0.23% | $642.65M | 0.2% |
STIP | -0.23% | $11.49B | 0.03% |
IAK | -0.23% | $788.23M | 0.39% |
MMIT | 0.24% | $830.69M | 0.3% |
DRLL | 0.24% | $302.90M | 0.41% |
VTIP | -0.25% | $13.57B | 0.03% |
SLVP | -0.25% | $266.22M | 0.39% |
VOX | 0.26% | $4.50B | 0.09% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
QETH | -12.76% | $15.06M | 0.25% |
CETH | -12.61% | $9.24M | 0% |
ETHA | -12.60% | $2.39B | 0.25% |
UNG | -12.58% | $413.30M | 1.06% |
EZET | -12.44% | $23.66M | 0% |
ETHV | -12.14% | $92.70M | 0% |
BTC | -10.93% | $3.28B | 0.15% |
ETHW | -10.66% | $191.08M | 0% |
RSPA | -10.51% | $293.87M | 0% |
FETH | -10.40% | $797.01M | 0.25% |
CPSJ | -10.39% | $33.06M | 0.69% |
ETH | -9.92% | $1.29B | 0% |
UUP | -9.63% | $328.64M | 0.77% |
USDU | -8.81% | $213.62M | 0.5% |
USO | -8.35% | $947.20M | 0.6% |
DBE | -8.05% | $54.74M | 0.77% |
UGA | -7.56% | $88.53M | 0.97% |
BNO | -7.30% | $96.15M | 1% |
CTA | -7.28% | $943.11M | 0.76% |
DBO | -7.20% | $199.76M | 0.77% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PGR | -<0.01% | $163.47B | +34.83% | 1.75% |
GCI | -<0.01% | $433.26M | +20.49% | 0.00% |
HIHO | 0.01% | $8.10M | -12.38% | 6.45% |
PFLT | -0.02% | - | - | 10.99% |
CORZ | -0.02% | $2.20B | +111.30% | 0.00% |
TRNO | -0.02% | $6.46B | -5.53% | 3.04% |
EZPW | 0.02% | $806.22M | +29.52% | 0.00% |
NTB | 0.03% | - | - | 4.58% |
SRRK | -0.03% | $3.11B | +84.91% | 0.00% |
EBF | 0.03% | $524.67M | +9.72% | 4.93% |
CCEP | -0.03% | $39.77B | +23.37% | 2.42% |
MITT | -0.03% | $222.14M | +22.39% | 7.81% |
EE | 0.03% | $668.11M | +74.72% | 0.61% |
NX | -0.03% | $901.63M | -50.33% | 1.70% |
AKRO | -0.04% | $3.40B | +69.12% | 0.00% |
EXTR | 0.04% | $1.85B | +20.45% | 0.00% |
INTA | 0.04% | $4.76B | +74.66% | 0.00% |
ECG | 0.04% | $1.85B | -26.16% | 0.00% |
TM | -0.05% | $234.23B | -28.85% | 1.48% |
EVTC | 0.05% | $2.33B | -8.15% | 0.55% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PDCO | -47.53% | $2.76B | +12.88% | 2.50% |
EQC | -33.46% | $172.95M | +25.09% | 0.00% |
CRK | -19.35% | $5.81B | +113.79% | 0.00% |
SFIX | -19.28% | $418.59M | +23.11% | 0.00% |
LQDT | -18.77% | $974.32M | +68.76% | 0.00% |
FIGS | -14.09% | $763.85M | -5.62% | 0.00% |
REVG | -13.26% | $1.66B | +45.22% | 0.70% |
DEO | -12.28% | $58.54B | -29.15% | 3.97% |
TW | -11.62% | $31.28B | +40.89% | 0.29% |
PSO | -11.61% | $10.85B | +21.35% | 1.93% |
BRFS | -11.20% | $5.53B | +7.53% | 0.00% |
RRC | -11.18% | $9.46B | +13.83% | 0.84% |
MSDL | -10.98% | $1.83B | -3.12% | 7.48% |
PAY | -10.95% | $3.29B | +15.82% | 0.00% |
CIG | -10.91% | $3.45B | -0.77% | 0.00% |
CVNA | -10.58% | $27.46B | +132.52% | 0.00% |
CNC | -10.58% | $29.78B | -23.50% | 0.00% |
AR | -10.43% | $12.35B | +36.86% | 0.00% |
CTRA | -10.28% | $21.88B | +2.69% | 2.96% |
MAGN | -10.17% | $647.11M | -29.69% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PINK | 18.06% | $142.47M | 0.5% |
SCYB | 17.54% | $1.00B | 0.03% |
ARKG | 17.47% | $971.04M | 0.75% |
EPHE | 17.41% | $93.91M | 0.59% |
HYGV | 16.78% | $1.42B | 0.37% |
KRBN | 16.52% | $172.54M | 0.85% |
HYLB | 16.51% | $3.91B | 0.05% |
BBHY | 16.41% | $943.69M | 0.07% |
XBI | 16.37% | $5.45B | 0.35% |
GNOM | 16.33% | $55.08M | 0.5% |
EWM | 16.28% | $252.43M | 0.5% |
IWC | 16.10% | $830.00M | 0.6% |
SJNK | 15.70% | $4.87B | 0.4% |
ARKX | 15.69% | $269.58M | 0.75% |
SHYG | 15.57% | $6.46B | 0.3% |
USHY | 15.20% | $20.07B | 0.08% |
HYDB | 15.01% | $1.63B | 0.35% |
JNK | 14.72% | $7.72B | 0.4% |
SPHY | 14.63% | $8.73B | 0.05% |
IBTF | 14.55% | $2.24B | 0.07% |
Current Value
$1.711 Year Return
Current Value
$1.711 Year Return